Description: Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Home Page: www.acrux.com.au
103-113, Stanley Street
West Melbourne,
VIC
3003
Australia
Phone:
61 3 8379 0100
Officers
| Name | Title |
|---|---|
| Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus | CEO, MD & Executive Director |
| Ms. Joanna Johnson B.E., BEc, ICAA | CFO & Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9129 |
| Price-to-Sales TTM: | 1.4323 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |